Quotient Sciences Names Thierry Van Nieuwenhove CEO

Quotient Sciences, a global pharmaceutical drug development and manufacturing accelerator, appointed Thierry Van Nieuwenhove as its new chief executive officer.

Thierry succeeds Mark Egerton who is retiring after 18 as CEO. As part of the leadership transition, the company named Wayne Hewett non-executive chairman.

Nieuwenhove joins Quotient with an extensive track record in the pharma and CDMO services industry spanning over 23 years, and with experience in both small molecules and biologics.

Nieuwenhove previously served as CEO of ABL Inc. Prior to this, he held various senior leadership roles in the CDMO industry, including as the president of the Synthesis business unit at Novasep, global head of business development at Lonza, and CEO of Minakem, the CDMO and API manufacturing division of Minafin Group.

Hewett is an industry veteran who brings more than three decades of board and leadership experience to the Company. He currently serves as chairman of Cambrex, a global CDMO that provides drug substance, drug product, and analytical services across the entire drug lifecycle. He also serves on the board of directors of The Home Depot, Inc, Wells Fargo, UPS and Lytx, and is a dedicated Senior Adviser to Permira.

Nieuwenhove said, “I am honored to join Quotient as its new CEO and lead a team dedicated to improving the lives of patients worldwide. I have admired the company’s strong development in recent years, building a global footprint and bringing its innovative translational pharmaceutics delivery platform to customers across the world. I’m grateful for the opportunity and looking forward to driving the business through its next phase of growth and continuing the team’s desire to accelerate the development of new medicines.”